Breaking News

Ocera Executives Depart Following Tranzyme Merger

By Kristin Brooks | December 12, 2013

Moore and Stanley to pursue other opportunities

David S. Moore, chief business officer at Ocera Therapeutics, is leaving the company to pursue other opportunities. Mr. Moore was a member of the management team at Tranzyme and continued his employment with Ocera following the merger of the companies in July 2013.
In addition, as part of the transition of Ocera's corporate headquarters to Palo Alto, CA, Rhonda L. Stanley, controller and principal accounting officer will be leaving the company. Jeryl L. Hilleman, Ocera's chief financial officer will assume the role of principal accounting officer and a controller has been hired in Palo Alto.
"We are grateful to David for his leadership in overseeing several aspects of our post-merger integration and streamlining," said Linda Grais, M.D., chief executive officer of Ocera. "We wish him the best in his future endeavors."
"It has been exciting to be part of a successful merger process, from the initial concept through completion of full integration. OCR-002 has great therapeutic potential for patients with liver disease, which is an important and growing market," said David Moore. "However, my background lies in sales and marketing, and I plan to return to working with commercial stage products."